Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Capital Expenditures (2022 - 2025)

Taysha Gene Therapies' Capital Expenditures history spans 4 years, with the latest figure at -$386000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 1202.86% year-over-year to -$386000.0; the TTM value through Sep 2025 reached $23000.0, down 99.4%, while the annual FY2024 figure was $374000.0, 90.33% down from the prior year.
  • Capital Expenditures for Q3 2025 was -$386000.0 at Taysha Gene Therapies, down from $388000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $16.3 million in Q2 2022 and bottomed at -$17.9 million in Q4 2022.
  • The 4-year median for Capital Expenditures is $35000.0 (2024), against an average of $310333.3.
  • The largest annual shift saw Capital Expenditures skyrocketed 18471.43% in 2023 before it crashed 1202.86% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$17.9 million in 2022, then skyrocketed by 119.23% to $3.4 million in 2023, then plummeted by 100.06% to -$2000.0 in 2024, then plummeted by 19200.0% to -$386000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Capital Expenditures are -$386000.0 (Q3 2025), $388000.0 (Q2 2025), and $23000.0 (Q1 2025).